ST Pharm (237690) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
27 Oct, 2026Executive summary
Q3 2026 revenue rose 19.1% YoY to KRW 97.6bn and operating profit increased 6.6% to KRW 15.7bn; net income fell 94.8% to KRW 0.9bn, mainly on FX losses.
Financial highlights
Gross profit was KRW 36.8bn vs. KRW 37.0bn YoY; cost of goods sold rose to KRW 60.8bn from KRW 44.9bn.
SG&A declined 5.3% YoY to KRW 21.1bn, while R&D expenses increased 21.0% to KRW 8.1bn.
Outlook and guidance
Small Molecule CDMO expects additional batches in 2027; further margin improvement is anticipated as optimization continues.
Commercial project growth supported Q3 sales; secured co-development projects from two new clients, including SmartCap, LNP and optimization services.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ST Pharm
- 1Q26 profit surged as oligo clinical sales and a $329m backlog supported growth.237690
Macquarie Asia Conference 2026 presentation - Oligo CDMO growth lifted 2Q25 revenue and margins as backlog reached $240M.237690Global Investors Conference 2025 presentation
- Oligo CDMO scale-up pairs RNA platform growth with biosimilar and drug pipeline catalysts.237690Korea Investors Conference 2025 presentation
- Oligo CDMO scale-up and RNA platforms anchor growth amid 2Q revenue pressure.237690Korea Investment Week 2024 presentation
- Oligo growth and backlog support the outlook amid lower FY revenue.237690Q4 2024
- Oligo CDMO lifted Q3 revenue 32.7% and operating profit 141.6% YoY.237690Q3 2025
- Oligo growth and capacity expansion contrasted with lower net income and customer concentration risks.237690Q1 2025
- Q3 sales grew, but CRO headwinds cut operating profit as oligo expansion underpinned the outlook.237690Q3 2024
- Q2 revenue grew 52.8% YoY as operating profit rebounded and oligonucleotide CDMO expanded.237690Q2 2025